Genetic Analysis and Natural Polymorphisms in HIV-1 gp41 Isolates from Maputo City, Mozambique

恩夫韦肽 第41页 病毒学 进入抑制剂 人类免疫缺陷病毒(HIV) 病毒进入 慢病毒 生物 病毒载量 医学 病毒 遗传学 病毒性疾病 病毒复制 抗原 表位
作者
Nália Ismael,Dulce Bila,Diana Mariani,Adolfo Vubil,Nédio Mabunda,Celina Monteiro Abreu,Ilesh Jani,Amílcar Tanuri
出处
期刊:AIDS Research and Human Retroviruses [Mary Ann Liebert]
卷期号:30 (6): 603-609 被引量:4
标识
DOI:10.1089/aid.2013.0244
摘要

Enfuvirtide was the first fusion inhibitor approved by the Food and Drug Administration (FDA) in 2003 for HIV-1 infection in treatment-experienced patient. It is the first approved antiviral agent to attack the HIV life cycle in its early stages. For HIV fusion to occur, the HR1 and HR2 domains in the gp41 region need to interact. Enfuvirtide is a synthetic peptide that corresponds to 36 amino acids of the HR2, which competitively binds to HR1 inhibiting the interaction with the HR2 domain thus preventing fusogenic conformation and inhibiting viral entry into host cells. Resistance to enfuvirtide is conferred by mutations occurring in the HR1 region involving residues 36-45. Mozambique, a sub-Saharan country, with an HIV prevalence of 11.5%, provides first line and second line antiretroviral therapy (ART)-based treatment. In poor resource settings such as Mozambique the lack of adequate infrastructures, the high costs of viral load tests, and the availability of salvage treatment have hindered the intended objective of monitoring HIV treatment, suggesting an important concern regarding the development of drug resistance. The general aim of this study was to evaluate naturally occurring polymorphisms and resistance-associated mutations in the gp41 region of HIV-1 isolates from Mozambique. The study included 78 patients naive to ARV treatment and 28 patients failing first line regimen recruited from Centro de Saúde Alto-Maé situated in Maputo. The gp41 gene from 103 patients was sequenced and resistance-associated mutations for enfuvirtide were screened. Subtype analysis revealed that 96% of the sequences were classified as subtype C, 2% as subtype G, 1% as subtype A1, and the other 1% as a mosaic form composed of A1/C. No enfuvirtide resistance-associated mutations in HR1 of gp41 were detected. The major polymorphisms in the HR1 were N42S, L54M, A67T, and V72I. This study suggests that this new class of antiviral drug may be effective as a salvage therapy in patients failing first line regimens in Mozambique. However, further phenotypic studies are required to determine the clinical relevance of the polymorphisms detected in this study.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
直率新柔完成签到 ,获得积分10
1秒前
yang完成签到,获得积分10
2秒前
2秒前
2秒前
tchao发布了新的文献求助10
3秒前
3秒前
4秒前
5秒前
6秒前
8秒前
9秒前
隐形啤酒发布了新的文献求助10
9秒前
10秒前
阔达魔镜发布了新的文献求助10
11秒前
zhaiping完成签到,获得积分10
11秒前
重要手机完成签到 ,获得积分10
11秒前
11秒前
11秒前
12秒前
CodeCraft应助小吴同志采纳,获得10
14秒前
14秒前
善良安南发布了新的文献求助10
14秒前
丘比特应助L912294993采纳,获得10
14秒前
SciGPT应助淋漓尽致采纳,获得10
14秒前
知知发布了新的文献求助10
15秒前
田様应助oso采纳,获得10
15秒前
等等发布了新的文献求助10
16秒前
旺旺碎碎冰完成签到,获得积分20
17秒前
wanci应助hhhh采纳,获得10
17秒前
xingxingwang发布了新的文献求助10
17秒前
18秒前
19秒前
苏书白应助阿兰采纳,获得30
20秒前
dmhsds发布了新的文献求助10
20秒前
M张发布了新的文献求助10
21秒前
所所应助坚果采纳,获得10
21秒前
21秒前
22秒前
方格发布了新的文献求助10
22秒前
zhou完成签到,获得积分10
23秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi 400
Classics in Total Synthesis IV 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3149952
求助须知:如何正确求助?哪些是违规求助? 2800974
关于积分的说明 7842886
捐赠科研通 2458475
什么是DOI,文献DOI怎么找? 1308544
科研通“疑难数据库(出版商)”最低求助积分说明 628524
版权声明 601721